Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

onger for STELARA patients (14.4 and 18.1 weeks for 45 and 90mg, respectively) than for etanercept patients (7.3 weeks).  Response was regained in 84 percent of patients following retreatment with two STELARA (45 mg or 90 mg) injections.

Through week 12 of the study, the percentages of study participants experiencing at least one adverse event (AE) were comparable between the STELARA 45 mg group (66 percent), the STELARA 90 mg group (69 percent) and the etanercept 50 mg group (70 percent).  Those patients experiencing at least one serious AE through week 12 were reported as follows: 1.9 percent and 1.2 percent of patients receiving STELARA 45 mg or 90 mg, respectively, compared with 1.2 percent of patients receiving etanercept.  Rates of specific AEs were generally comparable between treatment groups with the exception of injection site reactions, which were reported in 25 percent of patients treated with etanercept versus 4.3 percent and 3.7 percent with STELARA 45 mg and 90 mg, respectively, though this disparity may have been influenced by the greater number of etanercept injections administered (at least 24 in the 12-week portion of the study) compared with two STELARA injections.  

Through week 64, AEs were generally comparable between patients in the 45 mg (87 percent) and 90 mg (89 percent) STELARA groups.  In patients who crossed over from etanercept to STELARA, generally similar proportions experienced AEs (79 percent versus 65 percent) and serious AEs (3.5 percent versus 3.4 percent) before versus after transitioning to STELARA.

About the ACCEPT Trial

The Phase 3, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Ustekinumab Compared to Etanercept in the Treatment of Subjects with Moderate to Severe Plaque Psoriasis (ACCEPT) included 903 patients with chronic plaque psoriasis (etanercept=347, STELARA 45 mg=209, STELARA 90 mg=347).  Patients w
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby stopped ... to his lungs. April and Bryan Gionfriddo ... weren,t true. "Quite a few doctors said he ... says April Gionfriddo , about her now ... that would work, we would take it and run with ...
(Date:5/23/2013)... May 23, 2013   Direct to implant, ... is an appropriate option for many women with ... reduce their breast cancer risk, or with breast ... process and a second surgery to insert permanent ... same surgery as mastectomy can be a medically ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3
... ViroPharma Incorporated (Nasdaq: VPHM ) ... has granted ViroPharma an exclusive worldwide license to ... delivery platform using Halozyme,s recombinant human hyaluronidase enzyme ... inhibitor. Additionally, Halozyme has agreed not to grant to ...
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... dental, medical and veterinary practitioners, has been ranked number 317 ... Largest Corporations.  Henry Schein,s net sales reached a record $7.5 ... 500 rankings over the past three years, having been ranked ...
Cached Medicine Technology:ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 2ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 3ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 4ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 5ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 6ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 7Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of America's Largest Corporations 2
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... digestive problems, ranging from irritable bowel syndrome (IBS) ... problems are among the most long-lasting, embarrassing, frustrating ... natural foods for digestive health have ... While there are many factors contributing to digestive ...
(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... Vancouver, BC (PRWEB) May 25, 2013 ... of the most beautiful and powerful women that ever ... was felt by some of the most powerful men ... used many beauty remedies to keep her skin glowing ... treatments made with bees- wax, maringa oil and cyprus ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the Cell ... of 28.7% to $1.0 billion in the five years to ... 2008, no new cell therapy products were introduced, according to ... that period. In the years since, however, the Food and ... contributed to the industry's fast growth during the five years ...
(Date:5/25/2013)... 25, 2013 Ayurveda is the ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... order to re-establish optimal health, one must discover where we ... style which brings us back into perfect harmony. , The ...
Breaking Medicine News(10 mins):Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2
... April 28 AIDS Action Council commends President Obama and ... Goosby as Director of the Office of the Global AIDS ... of the Global AIDS Coordinator will be led by such ... experience in the breadth of global AIDS, including the epidemic ...
... 2009 (BRONX, NY) A laboratory study by researchers ... that an anti-cancer compound studied for treating blood cancers may ... The work is reported in the April 28th online edition ... neck cancer refers to tumors in the mouth, throat, or ...
... studies used to gain Food and Drug Administration approval of ... according to a report led by the University of Pittsburgh ... of the American Journal of Psychiatry , the study ... for these studies, and those who do not qualify are ...
... MCDONOUGH, Ga. , April 28 With growing ... the question has been raised, "Will face masks protect ... Encompass Group, the manufacturer of ProGear(TM), an innovative, technologically ... in the United States, stated, "At this time it ...
... Sciences, Inc. today announced that it named Dr. Robert ... a leader in pharmaceutical research to its Scientific Advisory ... & Development in 2008, and currently serves as a ... 2000 and has been responsible for all pharmaceutical research ...
... Starting to Embrace Use of Targeted Agents Despite ... Decision Resources WALTHAM, Mass., April 28 Decision ... advisory firms focusing on pharmaceutical and healthcare issues, ... Roche/Chugai,s Xeloda, Indian brand/generics (capecitabine) will dominate the ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
Medicine Products: